SOFT TISSUE & BONE SARCOMA GROUP
EORTC 1809 – STRASS II – A randomized phase III study of neoadjuvant chemotherapy followed by surgery versus surgery alone for patients with High Risk RetroPeritoneal Sarcoma (RPS)
Retroperitoneal sarcoma is a very rare tumour, occurring in 0.5 to 1.0 per 100,000 of the population. Diagnosis and treatment are challenging. The standard of care consists currently of surgery. Overall patient survival at 5 years following surgery is between
60 and 70%.
The EORTC 1809 STRASS II study is the first official trial looking into potential benefits of chemotherapy before surgery to improve disease control and survival in patients burdened by this rare cancer.
SOFT TISSUE & BONE SARCOMA GROUP
EORTC 1809 – STRASS II – A randomized phase III study of neoadjuvant chemotherapy followed by surgery versus surgery alone for patients with High Risk RetroPeritoneal Sarcoma (RPS)
Retroperitoneal sarcoma is a very rare tumour, occurring in 0.5 to 1.0 per 100,000 of the population. Diagnosis and treatment are challenging. The standard of care consists currently of surgery. Overall patient survival at 5 years following surgery is between
60 and 70%.
The EORTC 1809 STRASS II study is the first official trial looking into potential benefits of chemotherapy before surgery to improve disease control and survival in patients burdened by this rare cancer.
Clinical Trial
Phase III
Cancer type
Sarcoma
Set up
EORTC & Intergroups
Status
Recruiting
Clinical trial:
Phase III
Cancer type:
Sarcoma
Set up:
EORTC & Intergroups
Status:
Recruiting
KEY STUDY MILESTONES
-
EORTC Board endorsement
EORTC Board endorsement
- 04/11/2019
-
Regulatory submissions (start)
Regulatory submissions (start)
- 29/09/2020
-
First Site Active (FSA)
First Site Active (FSA)
- 20/01/2021
-
Last Patient In (LPI) – 250 patients
Last Patient In (LPI) – 250 patients
- February 2028
-
Publication of results
Publication of results
- June 2030
- 21/03/2018
-
Protocol Release
Protocol Release
- 28/05/2020
-
Database set-up
Database set-up
- 06/10/2020
-
First Patient In (FPI)
First Patient In (FPI)
- March 2026
-
Final Analysis Report (FAR)
Final Analysis Report (FAR)
- March 2028
-
Long-term patient Follow-up / End of Project
Long-term patient Follow-up / End of Project
KEY STUDY MILESTONES
-
EORTC Board endorsement
EORTC Board endorsement
- 04/11/2019
-
Regulatory submissions (start)
Regulatory submissions (start)
- 29/09/2020
-
First Site Active (FSA)
First Site Active (FSA)
- 20/01/2021
-
Last Patient In (LPI) – 250 patients
Last Patient In (LPI) – 250 patients
- February 2028
-
Publication of results
Publication of results
- June 2030
- 21/03/2018
-
Protocol Release
Protocol Release
- 28/05/2020
-
Database set-up
Database set-up
- 06/10/2020
-
First Patient In (FPI)
First Patient In (FPI)
- March 2026
-
Final Analysis Report (FAR)
Final Analysis Report (FAR)
- March 2028
-
Long-term patient Follow-up / End of Project
Long-term patient Follow-up / End of Project
A word from…
Study Coordinators
& Partners
Patients
A word from…
Study Co-ordinators & Partners
Patients
STUDY STATUS
To view the Study Status map, please flip your phone horizontally:
FUNDING PARTNERS
International grants
National grants
FUNDING PARTNERS
International grants
National grants
